View More Recent Stories

Mar 31, 2025 02:23PM Corcept Therapeutics (CORT) April 110 calls and April 80 puts active as share price up 95%
Mar 31, 2025 10:52AM Increasing unusual call option volume: XLI UMC MCHI FEZ DT ULCC MGA ZH TDS LXRX DESP CORT
Mar 31, 2025 08:02AM Corcept Therapeutics (CORT): Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
Mar 3, 2025 04:08PM Corcept Therapeutics (CORT): FDA Files New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism
Feb 26, 2025 04:09PM Corcept Therapeutics (CORT) Misses Q4 EPS by 12c, provides guidance
Feb 11, 2025 06:42AM Corcept Therapeutics (CORT) PT Raised to $115 at H.C. Wainwright
Feb 7, 2025 06:49AM H.C. Wainwright Reiterates Buy Rating on Corcept Therapeutics (CORT)
Jan 30, 2025 06:27AM Corcept Therapeutics (CORT) PT Raised to $130 at Canaccord Genuity
Dec 30, 2024 05:26PM Kuehn Law Encourages Investors of Corcept Therapeutics Inc. to Contact Law Firm
Dec 30, 2024 05:16PM Corcept Therapeutics (CORT) Submits NDA for Relacorilant as a Treatment for Patients With Hypercortisolism
Dec 16, 2024 08:06AM Corcept Therapeutics' (CORT) Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism
Dec 12, 2024 04:05PM Corcept Therapeutics (CORT) Reports Positive Results in Treatment Phase of CATALYST Trial
Dec 11, 2024 04:07PM Corcept Therapeutics (CORT) Announces Results From Phase 2 Study of Dazucorilant
Oct 31, 2024 07:58AM H.C. Wainwright Reiterates Buy Rating on Corcept Therapeutics (CORT)
Oct 30, 2024 04:20PM Corcept Therapeutics (CORT) Tops Q3 EPS by 13c, provides guidance
Oct 30, 2024 04:06PM Corcept Therapeutics (CORT) Reports Q3, Announces Positive Results From Phase 3 GRADIENT Trial
Oct 21, 2024 06:16AM Truist Securities Reiterates Buy Rating on Corcept Therapeutics (CORT)
Oct 20, 2024 10:00AM 4 biotech stocks to own to benefit from key Q4 catalysts
Oct 18, 2024 06:40AM Corcept Therapeutics (CORT) PT Raised to $80 at H.C. Wainwright
Sep 30, 2024 06:08AM Corcept Therapeutics (CORT) PT Raised to $76 at Truist Securities
Sep 25, 2024 07:06AM Canaccord Genuity Reiterates Buy Rating on Corcept Therapeutics (CORT)
Aug 15, 2024 06:50AM Canaccord Genuity Reiterates Buy Rating on Corcept Therapeutics (CORT)
Jul 31, 2024 06:27AM Corcept Therapeutics (CORT) PT Raised to $78 at Canaccord Genuity
Jul 30, 2024 07:10AM Corcept Therapeutics (CORT) PT Raised to $38 at Piper Sandler
Jul 30, 2024 06:44AM Corcept Therapeutics (CORT) PT Raised to $45 at H.C. Wainwright
Jul 29, 2024 04:18PM Corcept Therapeutics (CORT) Tops Q2 EPS by 9c
Jul 17, 2024 08:34AM Piper Sandler Reiterates Overweight Rating on Corcept Therapeutics (CORT)
Jul 1, 2024 07:14AM Piper Sandler Reiterates Overweight Rating on Corcept Therapeutics (CORT)
Jun 12, 2024 07:45AM Canaccord Genuity Reiterates Buy Rating on Corcept Therapeutics (CORT)
Jun 10, 2024 06:49AM Piper Sandler Reiterates Overweight Rating on Corcept Therapeutics (CORT)
View More Recent Stories